Overview

To Compare and Evaluate the Oral Bioavailability of Bilastine 20 mg Orally Dispersible Tablet With That of Bilaxten (Bilastine) 20 mg Orally Dispersible Tablet in Healthy, Adult, Human Subjects Under Fasting Conditions

Status:
COMPLETED

Trial end date:
2025-06-19

Target enrollment:

Participant gender:

Summary

An open label, balanced, randomized single-dose, two-treatment, two sequence, four-period, Full Replicate, crossover oral bioequivalence study in healthy, adult, human subjects under fasting condition.

Phase:

PHASE1

Details

Lead Sponsor:

Humanis Saglk Anonim Sirketi

Treatments:

bilastine